-+ 0.00%
-+ 0.00%
-+ 0.00%

Sagimet says Phase 1 trial shows denifanstat-resmetirom combo cuts LDL cholesterol in healthy adults

PUBT·05/27/2026 11:03:53
Listen to the news
Sagimet says Phase 1 trial shows denifanstat-resmetirom combo cuts LDL cholesterol in healthy adults
  • Sagimet Biosciences announced Phase 1 clinical results on denifanstat combined with resmetirom, presented for the first time at EASL 2026.
  • The study showed the combination was generally well-tolerated in healthy adults, with no safety signals reported over the trial period.
  • Data also indicated rapid improvements in cholesterol measures, supporting a potential cardiovascular benefit alongside the MASH rationale.
  • Preclinical findings will be presented at EASL 2026, pointing to complementary mechanisms that could strengthen anti-fibrotic and metabolic effects versus monotherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270700PRIMZONEFULLFEED9727043) on May 27, 2026, and is solely responsible for the information contained therein.